Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boehringer’s Novel Exercise Claims In COPD May Spur FDA Action To Clarify Requirements

Executive Summary

Company was hoping for an exercise tolerability claim for olodaterol, but members of the Pulmonary-Allergy Drugs Advisory Committee questioned several aspects of the trials and suggested FDA issue guidance on the matter.

You may also be interested in...



Striverdi Exercise Trials Tried, But Failed, To Control For Non-Disease Impacts

FDA questioned adherence to, and effectiveness of, measures aimed at minimizing exercise test performance variability in the trial Boehringer Ingelheim conducted to support exercise-related labeling claims for the COPD drug.

Novel COPD Exercise Claims Eluded Boehringer In Bid to Differentiate Striverdi

Sponsor’s claimed impact on exercise tolerance was not adequately supported and should not serve as a marketing advantage for the chronic obstructive pulmonary disease drug, FDA review staff said. However, Boehringer Ingelheim’s failed attempt for the exercise-related labeling language spurred the agency to clarify the types of studies and endpoints that potentially could support such claims.

Boehringer’s Striverdi Respimat Approved For COPD, But Without Exercise Claim

The long-acting beta agonist olodaterol cleared FDA for treatment of chronic obstructive pulmonary disease, but it didn’t gain the differentiating claim the German pharma was seeking.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1131849

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel